Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF).
Credit available for this activity expires: 9/29/2024
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu